Zaloguj się

Gotowe bibliografie tematyczne / DRUG DESIGNING / Książki

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: DRUG DESIGNING.

Książki na temat „DRUG DESIGNING”

Autor: Grafiati

Data publikacji: 11 września 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych książek naukowych na temat „DRUG DESIGNING”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj książki z różnych dziedzin i twórz odpowiednie bibliografie.

1

Kinam, Park, i Mrsny Randy J. 1955-, red. Controlled drug delivery: Designing technologies for the future. Washington, D.C: American Chemical Society, 2000.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Evans, David G. Designing an effective drug-free workplace compliance program. Deerfield, IL: Clark Boardman Callaghan, 1993.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Mayforth, Ruth D. Designing antibodies. San Diego: Academic Press, Inc., 1993.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

R, Antos Joseph, Spoor Christian i United States. Congressional Budget Office., red. Issues in designing a prescription drug benefit for Medicare. [Washington, D.C.]: Congress of the United States, Congressional Budget Office, 2002.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

1942-, Ellickson Phyllis L., red. Designing and implementing Project ALERT: A smoking and drug prevention experiment. Santa Monica, CA: RAND, 1988.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Loomis, Lloyd. Drug testing: A workplace guide to designing practical policies and winning arbitrations. Washington, D.C: Bureau of National Affairs, 1990.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Center, Joslin Diabetes, red. Joslin's insulin deskbook: Designing and initiating insulin treatment programs. Boston, MA: Joslin Diabetes Center, c2008., 2008.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Rahrer, J. Stuart. Preparing for tomorrow-- today: Designing a personalized plan to prevent your child's alcohol-drug abuse. Fort Wayne, IN: Pharos Consulting & Publications, 1997.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Barbara, Davis. Peer support: Designing interpersonal skills training plan. [Edmonton]: Alberta Alcohol and Drug Abuse Commission, 1989.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

March, Darren. Designing new antiviral drugs for AIDS: HIV-1 protease and its inhibitors. Austin: R.G. Landes, 1996.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Morphy, J. Richard, i C. John Harris, red. Designing Multi-Target Drugs. Cambridge: Royal Society of Chemistry, 2012. http://dx.doi.org/10.1039/9781849734912.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

12

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. Designing a twenty-first century Medicare prescription drug benefit: Hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Eighth Congress, first session, April 8, 2003. Washington: U.S. G.P.O., 2003.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

1936-, Martin Yvonne Connolly, i Willett Peter 1953-, red. Designing bioactive molecules: Three-dimensional techniques and applications. Washington, DC: American Chemical Society, 1998.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

1964-, Kimko Hui C., i Duffull Stephen B. 1964-, red. Simulation for designing clinical trials: A pharmacokinetic-pharmacodynamic modeling perspective. New York: Marcel Dekker, 2003.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

Barger, Raymond L. A method for designing blended wing-body configurations for low wave drag. [Washington, DC]: National Aeronautics and Space Administration, Office of Management, Scientific and Technical Information Program, 1992.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

Dashora, Kamlesh. Drug Designing. Discovery Publishing House Pvt Ltd, 2016.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

Kothekar, V. Essentials of Drug Designing. Dhruv Publications, 2005.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

18

Designing Multi-Target Drugs. Royal Society of Chemistry, The, 2012.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

19

Designing Hydrogels for Controlled Drug Delivery. MDPI, 2020. http://dx.doi.org/10.3390/books978-3-03928-357-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Sharma, Anju, Rajnish Kumar i Rajesh Kumar Tiwari. Introduction to Drug Designing and Development. Nova Science Publishers, Incorporated, 2014.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

Mani, Ashutosh. Recent Advances in Computer Aided Drug Designing. Nova Science Publishers, Incorporated, 2021.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

Mani, Ashutosh. Recent Advances in Computer Aided Drug Designing. Nova Science Publishers, Incorporated, 2021.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Gupta, Sikha. Insilico Screning & Drug Designing For Lipoic Acid-B Protein. LAP Lambert Academic Publishing, 2012.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

Antos, Joseph. Issues in Designing a Prescription Drug Benefit for Medicare. Diane Pub Co, 2003.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

(Editor), Kinam Park, i Randall J. Mrsny (Editor), red. Controlled Drug Delivery: Designing Technologies for the Future (Acs Symposium Series). An American Chemical Society Publication, 2000.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

26

Jojarth, Christine. Crime, War, and Global Trafficking: Designing International Cooperation. Cambridge University Press, 2009.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

27

Jojarth, Christine. Crime, War, and Global Trafficking: Designing International Cooperation. Cambridge University Press, 2009.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

28

Jojarth, Christine. Crime, War, and Global Trafficking: Designing International Cooperation. Cambridge University Press, 2009.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

29

Jojarth, Christine. Crime, War, and Global Trafficking: Designing International Cooperation. Cambridge University Press, 2009.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

30

Jojarth, Christine. Crime, War, and Global Trafficking: Designing International Cooperation. Cambridge University Press, 2009.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

31

A Practical Guide To Designing Phase Ii Trials In Oncology. John Wiley & Sons Inc, 2014.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

Designing Alcohol and Other Drug Prevention Programs in higher education: Bringing theory into practice. Newton, Mass: U.S. Dept. of Education, Office of Educational Research and Improvement, Educational Resources Information Center, 1997.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

33

O'Quigley, John, Alexia Iasonos i Bjö Bornkamp. Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

34

O'Quigley, John, Alexia Iasonos i Björn Bornkamp. Handbook of Methods for Designing Monitoring and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2019.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

O'Quigley, John, Alexia Iasonos i Bjö Bornkamp. Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

36

O'Quigley, John, Alexia Iasonos i Bjö Bornkamp. Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

37

Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

Bilirakis, Michael. Designing a Twenty-first Century Medicare Prescription Drug Benefit: Hearing Before the Comm. on Energy And Commerce, U.s. House of Representatives. Diane Pub Co, 2003.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

US GOVERNMENT. Designing a Twenty-First Century Medicare Prescription Drug Benefit: Hearing Before the Subcommittee on Health of the Committee on Energy and Commerce. Government Printing Office, 2003.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

40

National Aeronautics and Space Administration (NASA) Staff. Method for Designing Blended Wing-Body Configurations for Low Wave Drag. Independently Published, 2018.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

(Editor), M. G. Ford, i European Symposium on Quantitative Structure-Activity Relationships 20 (Editor), red. Euroqsar 2002 Designing Drugs and Crop Protectants: Processes, Problems and Solutions. Blackwell Publishers, 2003.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

O'Quigley, John, Alexia Iasonos i Bjö Bornkamp. Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Designing Bioactive Molecules: Three-Dimensional Techniques and Applications (Computer Applications in Chemistry Collection). An American Chemical Society Publication, 1998.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

Sjøgren, Per, Frank Elsner i Stein Kaasa. Non-opioid analgesics. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656097.003.0096.

Pełny tekst źródła

Streszczenie:

Non-opioid analgesics encompass the non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol (acetaminophen). The NSAIDs include acetylsalicylic acid (ASA, aspirin), dipyrone (metamizole), and numerous other drugs in diverse classes. The NSAIDs have potent anti-inflammatory, analgesic and antipyretic activity, and are among the most widely used drugs worldwide. In palliative medicine, they represent the first step of the World Health Organization’s analgesic ladder used for mild pain and they are an important supplement to opioids and adjuvant drugs at higher steps of the ladder. The disadvantages of non-opioid analgesics include a ceiling effect for pain relief and the risk of side effects. NSAIDs are also associated with an increased risk of adverse gastrointestinal, renal, and cardiovascular effects and hepatotoxicity can result from overdosing with paracetamol. This chapter describes the clinical pharmacology of NSAIDs, their classification, molecular mechanisms of action and adverse effects, as well as some recent developments aimed at designing effective anti-inflammatory agents with improved safety and tolerability profiles.

Style APA, Harvard, Vancouver, ISO itp.

45

Ray, Sumantra (Shumone), Sue Fitzpatrick, Rajna Golubic, Susan Fisher i Sarah Gibbings, red. Clinical trial design. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199608478.003.0014.

Pełny tekst źródła

Streszczenie:

This chapter outlines the various study designs and their uses. The phases of drug development are described and the appropriate study design employed at each phase of development is identified Elimination of bias is critical to the study design and methods of eliminating bias are discussed, defining the population, randomisation and blinding. A summary of the elements to be considered when designing a study are presented including the types of control, placebo or active, and their uses, Non comparative and comparative designs are presented. In the comparative design both within and between patient designs are discussed including crossover, parallel, sequential, factorial and left right comparisons. Patient outcomes measures as well as efficacy measurement are required for new treatments. There is a brief review of pharmaeconomic study designs. Other types of study design, dose escalation and dose response studies are also discussed. As well as reducing bias in studies another critical element is the recording of the primary assessment methods. The choice of methods will affect other aspects of the study such as the statistical considerations. The methodology must be standardised and validated.

Style APA, Harvard, Vancouver, ISO itp.

46

Wohlbier, Thomas. Nanohybrids. Materials Research Forum LLC, 2021. http://dx.doi.org/10.21741/9781644901076.

Pełny tekst źródła

Streszczenie:

The book covers preparation, designing and utilization of nanohybrid materials for biomedical applications. These materials can improve the effectiveness of drugs, promote high cell growth in new scaffolds, and lead to biodegradable surgical sutures. The use of hybrid magneto-plasmonic nanoparticles may lead to non-invasive therapies. The most promising materials are based on silica nanostructures, polymers, bioresorbable metals, liposomes, biopolymeric electrospun nanofibers, graphene, and gelatin. Much research focuses on the development of biomaterials for cell regeneration and wound healing applications.

Style APA, Harvard, Vancouver, ISO itp.

47

Simulation for Designing Clinical Trials: A Pharmacokinetic-Pharmacodynamic Modeling Perspective (Drugs and the Pharmaceutical Sciences, Vol 127) (Drugs and the Pharmaceutical Sciences). Informa Healthcare, 2002.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Mills, Gary H. Under-representation of older people in clinical trials. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689644.003.0016.

Pełny tekst źródła

Streszczenie:

Key points• Older people, often with high levels of co-morbidity and polypharmacy, are increasing in number as the population ages.• Study populations in clinical trials have often not mirrored the population that will consume the drugs or treatments being investigated.• Regulators, ethics committees, and funding bodies must recognize the need for inclusion of older people and the complexities this imposes on investigators.• Across all aspects of medicine, funding for research into how best to safely include older people in clinical trials is vital.• Researchers should not be disadvantaged by designing studies to meet the needs of the age range of patients expected to receive the treatment being investigated; this should include provision for older people.

Style APA, Harvard, Vancouver, ISO itp.

49

Grant, Robert. Tumours of the brain and skull. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780198569381.003.0624.

Pełny tekst źródła

Streszczenie:

Over the last 10 years, there have been several important advances in cell biology, molecular genetics, and targeted therapies in neuro-oncology. Improved neurosurgical techniques such as frameless stereotaxy, awake craniotomy, and intra-operative MRI, safer methods of directing radiotherapy, new chemotherapy approaches, and novel modalities of therapy provide optimism that there will eventually be some improvements in treatment-related morbidity and survival. There has also been an increasing change from individual clinician decision making to decision making by multidisciplinary teams of neurosurgeons, neurologists, clinical oncologists, neuropathologists, neuroradiologists, and specialist nurses with the aim of improving decision making, management planning across specialties, communication, and enrolment in suitable clinical trials. In addition, Good Clinical Practice guidelines, an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials, increases the onus and responsibilities on clinical investigators to perform trials to the highest standard and to have the trials externally monitored, and the trial conduct and results audited. While these obligatory and statutory responsibilities are labour intensive and time consuming, they should improve the quality of trials by limiting the possibility of unintentional bias or fraud. Improving the recording of serious adverse event reporting through trial quality assurance and quality control procedures will help ensure that a balanced view of the effects of a drug or procedure is identified earlier than in the past. It will be interesting to see how research develops over the next decade.

Style APA, Harvard, Vancouver, ISO itp.

50

Knaggs, Roger D. The molecular structure of the μ‎-opioid receptor. Redaktorzy Paul Farquhar-Smith, Pierre Beaulieu i Sian Jagger. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198834359.003.0038.

Pełny tekst źródła

Streszczenie:

The landmark paper discussed in this chapter describes the crystal structure of the μ‎-opioid receptor (also known as MOP-1). Opioids are some of the oldest known drugs and have been used for over 4,000 years; however, in addition to having beneficial analgesic effects, they are associated with a myriad of side effects that can minimize their use. Although the gene sequences of the opioid receptors were determined in the 1990s it has taken much longer to translate this into visualizing their three-dimensional structure. The μ‎-opioid receptor consists of seven transmembrane α‎-helices that are connected by three extracellular loops and three intracellular loops, with a wide open binding pocket which offers many potential ligand interaction sites, and evidence of dimerization. Understanding the crystal structure of the μ‎-opioid receptor in much more detail aids explanation of the molecular determinants of ligand recognition and selectivity and will be of use in designing novel opioids with improved efficacy and fewer side effects.

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!